Compare VERU & MVIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERU | MVIS |
|---|---|---|
| Founded | 1971 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.9M | 45.0M |
| IPO Year | 1996 | 2010 |
| Metric | VERU | MVIS |
|---|---|---|
| Price | $2.21 | $1.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $25.67 | N/A |
| AVG Volume (30 Days) | 212.5K | ★ 1.2M |
| Earning Date | 08-10-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,296,958.00 | $664,000.00 |
| Revenue This Year | N/A | $1,017.55 |
| Revenue Next Year | N/A | $48.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.05 | $0.23 |
| 52 Week High | $7.33 | $4.90 |
| Indicator | VERU | MVIS |
|---|---|---|
| Relative Strength Index (RSI) | 39.74 | 46.10 |
| Support Level | $2.11 | $0.56 |
| Resistance Level | $2.68 | $1.89 |
| Average True Range (ATR) | 0.14 | 0.11 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 19.77 | 36.33 |
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars. Geographically, the company operates in United States, Germany, and Other foreign countries.